Related Experiment Video
Updated: Jul 10, 2026

Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections
Published on: October 31, 2017
Thymalfasin: clinical pharmacology and antiviral applications
A Gramenzi1, C Cursaro, P Andreone
1Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, University of Bologna, Bologna, Italy.
Thymalfasin (thymosin-alpha1) is an immunomodulatory agent that is able to augment some specific T lymphocyte functions, particularly that of promoting the T helper 1 cell responses involved in host antiviral defence. The most promising clinical applications for thymalfasin seem to be as a single agent for the treatment of chronic hepatitis B and in combination with interferon-alpha for the treatment of both chronic hepatitis B and C. These positive preliminary results offer a strong rationale for larger, well-planned clinical trials and also for defining the optimal schedule of administration.
Thymalfasin (thymosin-alpha1) is an immunomodulatory agent that is able to augment some specific T lymphocyte functions, particularly that of promoting the T helper 1 cell responses involved in host antiviral defence. The most promising clinical applications for thymalfasin seem to be as a single agent for the treatment of chronic hepatitis B and in combination with interferon-alpha for the treatment of both chronic hepatitis B and C. These positive preliminary results offer a strong rationale for larger, well-planned clinical trials and also for defining the optimal schedule of administration.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Antifungal Agents
Inhibitors Of Virion Release
Subviral Agents
Inhibitors of Virion Maturation and Assembly

